SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS, INC (SGMO): 12 pipeline candidates · ~5 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.7 months
D/E -4.16
Lead: Approved
12 candidates
N/A
0 buys · 2 sells (180d)
A transparent, data-derived signal for SANGAMO THERAPEUTICS, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$74.0M
Cash
$27.6M
Quarterly Burn
$19.3M
Runway
4.7 mo
Revenue
$1.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| BIVV003 | Phase 1 |
| Busulfan | Phase 1 |
| giroctocogene fitelparvovec | Approved |
| Giroctocogene fitelparvovec (SB-525) | Phase 3 |
| isaralgagene civaparvovec | Phase 1/Phase 2 |
| Isaralgagene civaparvovec (ST-920) | Phase 1/Phase 2 |
| Plerixafor | Phase 1 |
| ST-400 | — |
| ST-503 | Phase 1/Phase 2 |
| st-506 | Phase 1/Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
113
Total value held
$29.0M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 40,400,067 | $10.0M |
| vanguard capital management llc | 25,408,816 | $6.3M |
| two sigma investments, lp | 6,270,441 | $1.5M |
| balyasny asset management l.p. | 5,288,097 | $1.3M |
| geode capital management, llc | 4,570,862 | $1.1M |
| blackrock, inc. | 4,547,848 | $1.1M |
| renaissance technologies llc | 3,836,665 | $947K |
| susquehanna international group, llp | 2,752,363 | $683K |
| charles schwab investment management inc | 2,352,360 | $581K |
| vanguard fiduciary trust co | 2,310,297 | $571K |
Showing top 10 of 113 institutional holders of SANGAMO THERAPEUTICS, INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SANGAMO THERAPEUTICS, INC's pipeline?
SANGAMO THERAPEUTICS, INC (SGMO) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SANGAMO THERAPEUTICS, INC's lead drug candidate?
SANGAMO THERAPEUTICS, INC's most advanced tracked candidate is BIVV003 (Phase 1) for Sickle Cell Disease; Blood and Lymphatic Diseases.
What is SANGAMO THERAPEUTICS, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SANGAMO THERAPEUTICS, INC has approximately 4.7 months of cash runway.
What is SANGAMO THERAPEUTICS, INC's market capitalization?
SANGAMO THERAPEUTICS, INC's market capitalization is approximately $74.0M.
Who is the CEO of SANGAMO THERAPEUTICS, INC?
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. is the chief executive officer of SANGAMO THERAPEUTICS, INC (SGMO).
Get the full picture on SANGAMO THERAPEUTICS, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.